Thursday, November 21, 2024 11/21/2024

A Novel Oral Insulin Enabling Safe and Efficient Gastrointestinal Transport and Absorption

Award Number: R01DK123293
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Abstract

Project Summary Oral insulin will improve the life quality of diabetes patients but current oral protein formulations face multiple obstacles during their gastrointestinal transport and absorption resulting in low therapeutic functionality. In particular, penetrating the intestinal mucus layer and the epithelial cell layer to reach the blood remained two major challenges for any oral formulation. Despite advancement in mucus-penetrating and absorption-enhancing technologies, current oral delivery of protein drugs remains low in absorption and bioavailability, and/or increases the risk of leaky gut and safety concerns such as autoimmune disease, bacterial infection and inflammatory bowel diseases. There is an urgent need for a safe and efficient oral delivery technology to drastically enhance protein transport through the mucus and intestinal epithelium, and to enable oral insulin with high bioavailability. The long-term research goal of the PI is to develop a platform technology that addresses these barriers altogether and enables oral insulin feasible for clinical translation. The objective of this project is to explore the mechanism for a novel insulin delivery system in addressing the mucus transport, epithelium absorption, and gut- related safety issues and contributing to a high oral bioavailability. Specific aims include the identification of mechanism/key parameters of the delivery system contributing to the preferred properties and performance in addressing these obstacles through in vitro and in vivo studies (involving diabetic mice and rats). Furthermore, this project will validate the feasibility of the oral insulin prototype on diabetic minipigs, which is a more relevant large animal model for predicting oral bioavailability in humans. The success of this project will directly lead to the development of highly promising oral insulin– a life-changing treatment for diabetes patients. This project will also produce foundational knowledge regarding how the particular delivery platform addresses the multiple barriers for oral protein delivery; this will impact a broad range of future development of oral protein drugs.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2022	WAYNE STATE UNIVERSITY	5700 CASS AVE STE 4900	DETROIT	MI	48202	WAYNE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	10/16/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $425,111 )
2022	2022	WAYNE STATE UNIVERSITY	5057 WOODWARD STE 13001	DETROIT	MI	48202	WAYNE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	5/30/2022	NON-COMPETING CONTINUATION	$425,111
														Subtotal = $425,111

Issue Date FY: 2021 ( Subtotal = $425,111 )
2021	2021	WAYNE STATE UNIVERSITY	5057 WOODWARD STE 13001	DETROIT	MI	48202	WAYNE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	5/27/2021	NON-COMPETING CONTINUATION	$425,111
														Subtotal = $425,111

Issue Date FY: 2020 ( Subtotal = $425,111 )
2020	2020	WAYNE STATE UNIVERSITY	5057 WOODWARD STE 13001	DETROIT	MI	48202	WAYNE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	5/12/2020	NON-COMPETING CONTINUATION	$425,111
														Subtotal = $425,111

Issue Date FY: 2019 ( Subtotal = $425,111 )
2019	2019	WAYNE STATE UNIVERSITY	5057 WOODWARD 13 FLOOR	DETROIT	MI	48202	WAYNE	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	9/20/2019	NEW	$425,111
														Subtotal = $425,111

Grand Total All Awards = $1,700,444

Top

All Categories

About

Search

Reports

Data Submission

Award Information

A Novel Oral Insulin Enabling Safe and Efficient Gastrointestinal Transport and Absorption

Award Number: R01DK123293

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer